MMP-9 responsive PEG cleavable nanovesicles for efficient delivery of chemotherapeutics to pancreatic cancer

Prajakta S. Kulkarni, Manas K. Haldar, Rahul R. Nahire, Preeya Katti, Avinash H. Ambre, Wallace W. Muhonen, John B. Shabb, Sathish K.R. Padi, Raushan K. Singh, Pawel P. Borowicz, D. K. Shrivastava, Kalpana S. Katti, Katie Reindl, Bin Guo, Sanku Mallik

Research output: Contribution to journalArticle

47 Citations (Scopus)

Abstract

Significant differences in biochemical parameters between normal and tumor tissues offer an opportunity to chemically design drug carriers which respond to these changes and deliver the drugs at the desired site. For example, overexpression of the matrix metalloproteinase-9 (MMP-9) enzyme in the extracellular matrix of tumor tissues can act as a trigger to chemically modulate the drug delivery from the carriers. In this study, we have synthesized an MMP-9-cleavable, collagen mimetic lipopeptide which forms nanosized vesicles with the POPC, POPE-SS-PEG, and cholesteryl-hemisuccinate lipids. The lipopeptide retains the triple-helical conformation when incorporated into these nanovesicles. The PEG groups shield the substrate lipopeptides from hydrolysis by MMP-9. However, in the presence of elevated glutathione levels, the PEG groups are reductively removed, exposing the lipopeptides to MMP-9. The resultant peptide-bond cleavage disturbs the vesicles lipid bilayer, leading to the release of encapsulated contents. These PEGylated nanovesicles are capable of encapsulating the anticancer drug gemcitabine with 50% efficiency. They were stable in physiological conditions and in human serum. Effective drug release was demonstrated using the pancreatic ductal carcinoma cells (PANC-1 and MIAPaCa-2) in two-dimensional and three-dimensional "tumor-like" spheroid cultures. A reduction in tumor growth was observed after intravenous administration of the gemcitabine-encapsulated nanovesicles in the xenograft model of athymic, female nude mice.

Original languageEnglish (US)
Pages (from-to)2390-2399
Number of pages10
JournalMolecular Pharmaceutics
Volume11
Issue number7
DOIs
StatePublished - Jul 7 2014

Fingerprint

Lipopeptides
Matrix Metalloproteinase 9
gemcitabine
Pancreatic Neoplasms
Drug Carriers
Neoplasms
Pancreatic Ductal Carcinoma
Lipid Bilayers
Heterografts
Nude Mice
Pharmaceutical Preparations
Intravenous Administration
Extracellular Matrix
Glutathione
Hydrolysis
Collagen
Lipids
Peptides
Enzymes
Growth

Keywords

  • drug delivery
  • drug release
  • matrix metalloproteinase-9
  • nanoparticle
  • pancreatic cancer cell spheroids
  • peptide

ASJC Scopus subject areas

  • Molecular Medicine
  • Pharmaceutical Science
  • Drug Discovery

Cite this

Kulkarni, P. S., Haldar, M. K., Nahire, R. R., Katti, P., Ambre, A. H., Muhonen, W. W., ... Mallik, S. (2014). MMP-9 responsive PEG cleavable nanovesicles for efficient delivery of chemotherapeutics to pancreatic cancer. Molecular Pharmaceutics, 11(7), 2390-2399. https://doi.org/10.1021/mp500108p

MMP-9 responsive PEG cleavable nanovesicles for efficient delivery of chemotherapeutics to pancreatic cancer. / Kulkarni, Prajakta S.; Haldar, Manas K.; Nahire, Rahul R.; Katti, Preeya; Ambre, Avinash H.; Muhonen, Wallace W.; Shabb, John B.; Padi, Sathish K.R.; Singh, Raushan K.; Borowicz, Pawel P.; Shrivastava, D. K.; Katti, Kalpana S.; Reindl, Katie; Guo, Bin; Mallik, Sanku.

In: Molecular Pharmaceutics, Vol. 11, No. 7, 07.07.2014, p. 2390-2399.

Research output: Contribution to journalArticle

Kulkarni, PS, Haldar, MK, Nahire, RR, Katti, P, Ambre, AH, Muhonen, WW, Shabb, JB, Padi, SKR, Singh, RK, Borowicz, PP, Shrivastava, DK, Katti, KS, Reindl, K, Guo, B & Mallik, S 2014, 'MMP-9 responsive PEG cleavable nanovesicles for efficient delivery of chemotherapeutics to pancreatic cancer', Molecular Pharmaceutics, vol. 11, no. 7, pp. 2390-2399. https://doi.org/10.1021/mp500108p
Kulkarni, Prajakta S. ; Haldar, Manas K. ; Nahire, Rahul R. ; Katti, Preeya ; Ambre, Avinash H. ; Muhonen, Wallace W. ; Shabb, John B. ; Padi, Sathish K.R. ; Singh, Raushan K. ; Borowicz, Pawel P. ; Shrivastava, D. K. ; Katti, Kalpana S. ; Reindl, Katie ; Guo, Bin ; Mallik, Sanku. / MMP-9 responsive PEG cleavable nanovesicles for efficient delivery of chemotherapeutics to pancreatic cancer. In: Molecular Pharmaceutics. 2014 ; Vol. 11, No. 7. pp. 2390-2399.
@article{3a7843ddc2cc42f699e08c134275687d,
title = "MMP-9 responsive PEG cleavable nanovesicles for efficient delivery of chemotherapeutics to pancreatic cancer",
abstract = "Significant differences in biochemical parameters between normal and tumor tissues offer an opportunity to chemically design drug carriers which respond to these changes and deliver the drugs at the desired site. For example, overexpression of the matrix metalloproteinase-9 (MMP-9) enzyme in the extracellular matrix of tumor tissues can act as a trigger to chemically modulate the drug delivery from the carriers. In this study, we have synthesized an MMP-9-cleavable, collagen mimetic lipopeptide which forms nanosized vesicles with the POPC, POPE-SS-PEG, and cholesteryl-hemisuccinate lipids. The lipopeptide retains the triple-helical conformation when incorporated into these nanovesicles. The PEG groups shield the substrate lipopeptides from hydrolysis by MMP-9. However, in the presence of elevated glutathione levels, the PEG groups are reductively removed, exposing the lipopeptides to MMP-9. The resultant peptide-bond cleavage disturbs the vesicles lipid bilayer, leading to the release of encapsulated contents. These PEGylated nanovesicles are capable of encapsulating the anticancer drug gemcitabine with 50{\%} efficiency. They were stable in physiological conditions and in human serum. Effective drug release was demonstrated using the pancreatic ductal carcinoma cells (PANC-1 and MIAPaCa-2) in two-dimensional and three-dimensional {"}tumor-like{"} spheroid cultures. A reduction in tumor growth was observed after intravenous administration of the gemcitabine-encapsulated nanovesicles in the xenograft model of athymic, female nude mice.",
keywords = "drug delivery, drug release, matrix metalloproteinase-9, nanoparticle, pancreatic cancer cell spheroids, peptide",
author = "Kulkarni, {Prajakta S.} and Haldar, {Manas K.} and Nahire, {Rahul R.} and Preeya Katti and Ambre, {Avinash H.} and Muhonen, {Wallace W.} and Shabb, {John B.} and Padi, {Sathish K.R.} and Singh, {Raushan K.} and Borowicz, {Pawel P.} and Shrivastava, {D. K.} and Katti, {Kalpana S.} and Katie Reindl and Bin Guo and Sanku Mallik",
year = "2014",
month = "7",
day = "7",
doi = "10.1021/mp500108p",
language = "English (US)",
volume = "11",
pages = "2390--2399",
journal = "Molecular Pharmaceutics",
issn = "1543-8384",
publisher = "American Chemical Society",
number = "7",

}

TY - JOUR

T1 - MMP-9 responsive PEG cleavable nanovesicles for efficient delivery of chemotherapeutics to pancreatic cancer

AU - Kulkarni, Prajakta S.

AU - Haldar, Manas K.

AU - Nahire, Rahul R.

AU - Katti, Preeya

AU - Ambre, Avinash H.

AU - Muhonen, Wallace W.

AU - Shabb, John B.

AU - Padi, Sathish K.R.

AU - Singh, Raushan K.

AU - Borowicz, Pawel P.

AU - Shrivastava, D. K.

AU - Katti, Kalpana S.

AU - Reindl, Katie

AU - Guo, Bin

AU - Mallik, Sanku

PY - 2014/7/7

Y1 - 2014/7/7

N2 - Significant differences in biochemical parameters between normal and tumor tissues offer an opportunity to chemically design drug carriers which respond to these changes and deliver the drugs at the desired site. For example, overexpression of the matrix metalloproteinase-9 (MMP-9) enzyme in the extracellular matrix of tumor tissues can act as a trigger to chemically modulate the drug delivery from the carriers. In this study, we have synthesized an MMP-9-cleavable, collagen mimetic lipopeptide which forms nanosized vesicles with the POPC, POPE-SS-PEG, and cholesteryl-hemisuccinate lipids. The lipopeptide retains the triple-helical conformation when incorporated into these nanovesicles. The PEG groups shield the substrate lipopeptides from hydrolysis by MMP-9. However, in the presence of elevated glutathione levels, the PEG groups are reductively removed, exposing the lipopeptides to MMP-9. The resultant peptide-bond cleavage disturbs the vesicles lipid bilayer, leading to the release of encapsulated contents. These PEGylated nanovesicles are capable of encapsulating the anticancer drug gemcitabine with 50% efficiency. They were stable in physiological conditions and in human serum. Effective drug release was demonstrated using the pancreatic ductal carcinoma cells (PANC-1 and MIAPaCa-2) in two-dimensional and three-dimensional "tumor-like" spheroid cultures. A reduction in tumor growth was observed after intravenous administration of the gemcitabine-encapsulated nanovesicles in the xenograft model of athymic, female nude mice.

AB - Significant differences in biochemical parameters between normal and tumor tissues offer an opportunity to chemically design drug carriers which respond to these changes and deliver the drugs at the desired site. For example, overexpression of the matrix metalloproteinase-9 (MMP-9) enzyme in the extracellular matrix of tumor tissues can act as a trigger to chemically modulate the drug delivery from the carriers. In this study, we have synthesized an MMP-9-cleavable, collagen mimetic lipopeptide which forms nanosized vesicles with the POPC, POPE-SS-PEG, and cholesteryl-hemisuccinate lipids. The lipopeptide retains the triple-helical conformation when incorporated into these nanovesicles. The PEG groups shield the substrate lipopeptides from hydrolysis by MMP-9. However, in the presence of elevated glutathione levels, the PEG groups are reductively removed, exposing the lipopeptides to MMP-9. The resultant peptide-bond cleavage disturbs the vesicles lipid bilayer, leading to the release of encapsulated contents. These PEGylated nanovesicles are capable of encapsulating the anticancer drug gemcitabine with 50% efficiency. They were stable in physiological conditions and in human serum. Effective drug release was demonstrated using the pancreatic ductal carcinoma cells (PANC-1 and MIAPaCa-2) in two-dimensional and three-dimensional "tumor-like" spheroid cultures. A reduction in tumor growth was observed after intravenous administration of the gemcitabine-encapsulated nanovesicles in the xenograft model of athymic, female nude mice.

KW - drug delivery

KW - drug release

KW - matrix metalloproteinase-9

KW - nanoparticle

KW - pancreatic cancer cell spheroids

KW - peptide

UR - http://www.scopus.com/inward/record.url?scp=84903977849&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84903977849&partnerID=8YFLogxK

U2 - 10.1021/mp500108p

DO - 10.1021/mp500108p

M3 - Article

VL - 11

SP - 2390

EP - 2399

JO - Molecular Pharmaceutics

JF - Molecular Pharmaceutics

SN - 1543-8384

IS - 7

ER -